PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28373435
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170413
LR  - 20170413
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 4
DP  - 2017 Apr
TI  - Clinical Significance of DNA Damage Response Factors and Chromosomal Instability 
      in Primary Lung Adenocarcinoma.
PG  - 1729-1735
AB  - AIM: The purpose of this study was to investigate the biological role of DNA
      damage-response genes and chromosomal instability in primary lung adenocarcinoma.
      MATERIALS AND METHODS: We investigated 60 surgically-resected lung
      adenocarcinomas. Levels of checkpoint kinase 2 gene (CHEK2) and breast cancer
      type 1 susceptibility protein gene (BRCA1) mRNA expression were evaluated by
      polymerase chain reaction (PCR). Epidermal growth factor receptor (EGFR)
      mutations (exon 19 deletion and exon 21 mutation) were detected by the PCR clamp 
      method. Mutations in Kirsten rat sarcoma viral oncogene homolog gene (KRAS) and
      TP53 were examined by direct sequencing. Expression levels of p27 and p16
      proteins were assessed by immunohistochemistry. Chromosomal aberrations (CA) were
      examined in 20 samples with single-nucleotide polymorphism-comparative genomic
      hybridization. RESULTS: CHEK2 mRNA levels were significantly increased in tumor
      tissues compared to normal tissues (p=0.0123, paired t-test), whereas BRCA mRNA
      levels were not increased. TP53 mutation positivity and BRCA1 mRNA expression
      were positively associated with CHEK2 mRNA expression status (p=0.022 and
      p=0.0008). High CHEK2 mRNA expression was associated with poor recurrence-free
      survival (p=0.028). CHEK2 mRNA levels were higher in samples with a high CA
      frequency than in those with a low CA frequency (averages: 0.326 vs. 0.185;
      p=0.0129). CONCLUSION: The CHEK2 mRNA expression level was found elevated in lung
      adenocarcinoma and was related to a poor prognostic outcome. The CHEK2 pathway
      may be important for the proliferation of lung adenocarcinoma, especially in
      tumors with chromosomal instability.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Okamoto, Tatsuro
AU  - Okamoto T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan [email protected]
FAU - Kohno, Mikihiro
AU  - Kohno M
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Ito, Kensaku
AU  - Ito K
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Takada, Kazuki
AU  - Takada K
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Katsura, Masakazu
AU  - Katsura M
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Morodomi, Yosuke
AU  - Morodomi Y
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Toyokawa, Gouji
AU  - Toyokawa G
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Shoji, Fumihiro
AU  - Shoji F
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
FAU - Maehara, Yoshihiko
AU  - Maehara Y
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu
      University, Fukuoka, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (KRAS protein, human)
RN  - EC 2.7.1.11 (Checkpoint Kinase 2)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (Receptor, Epidermal Growth Factor)
RN  - EC 2.7.11.1 (CHEK2 protein, human)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Adenocarcinoma/*genetics/metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - BRCA1 Protein/genetics/*metabolism
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Case-Control Studies
MH  - Checkpoint Kinase 2/genetics/*metabolism
MH  - Chromosomal Instability/*genetics
MH  - Comparative Genomic Hybridization
MH  - DNA Damage/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Lung/metabolism/pathology
MH  - Lung Neoplasms/*genetics/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Mutation/genetics
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptor, Epidermal Growth Factor/genetics
MH  - Survival Rate
MH  - ras Proteins/genetics
OTO - NOTNLM
OT  - *BRCA1
OT  - *CHEK2
OT  - *DNA damage response
OT  - *chromosomal instability
OT  - *non-small cell lung cancer
OT  - *prognosis
EDAT- 2017/04/05 06:00
MHDA- 2017/04/14 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/02/12 [received]
PHST- 2017/03/09 [revised]
PHST- 2017/03/10 [accepted]
AID - 37/4/1729 [pii]
AID - 10.21873/anticanres.11505 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Apr;37(4):1729-1735.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>